Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Summary

This international, multi-center, open-label, single-arm study evaluated the safety and tolerability profile of everolimus in post-menopausal women with HR positive, HER2 negative locally advanced or metastatic breast cancer after documented recurrence or progression following a non-steroidal aromatase inhibitors (NSAI) therapy in Novartis Oncology emergent growth market (EGM) countries.Data was presented by Asian countries vs Non-Asian countries to confirm no difference in safety and efficacy. Summary statistics were presented.

Timeline

Start

2013-03-29

Primary completion

2019-01-29

Completion

2019-01-29

Drugs

Indications